|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study显示文摘 | Caicun Zhou Yi-Long Wu Gongyan Chen Jifeng Feng Xiao-Qing Liu Changli Wang Shucai Zhang Jie Wang Songwen Zhou Shengxiang Ren Shun Lu Li Zhang Chengping Hu Chunhong Hu Yi Luo Lei Chen Ming Ye Jianan Huang Xiuyi Zhi Yiping Zhang Qingyu Xiu Jun Ma Li Zhang C | 2011 | Lancet Oncology2011，，8： | 7 |
| 2 | Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)显示文摘Patients with small-cell lung cancer (SCLC) relapse within months after completing previous therapies. This study aimed to investigate the efficacy and safety of anlotinib as third- or further-line therapy in patients with short-term relapsed SCLC from ALTER1202. Patients with short-term relapsed SCLC (disease progression within 3 months after completing ≥ two lines of chemotherapy) in the anlotinib (n = 67) and placebo (n = 34) groups were analyzed. The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival, objective response rate (ORR), disease control rate, and safety. Anlotinib significantly improved median PFS/OS (4.0 vs. 0.7 months, P < 0.0001)/(7.3 vs. 4.4 months, P = 0.006) compared with placebo. The ORR was 4.5%/2.9% in the anlotinib/placebo group (P = 1.000). The DCR in the anlotinib group was higher than that in the placebo group (73.1% vs. 11.8%, P < 0.001). The most common adverse events (AEs) were hypertension (38.8%), loss of appetite (28.4%), and fatigue (22.4%) in the anlotinib group and gamma-glutamyl transpeptidase elevation (20.6%) in the placebo group. No grade 5 AEs occurred. For patients with short-term relapsed SCLC, third- or further-line anlotinib treatment was associated with improved survival benefit. Further studies are warranted in this regard. | Jianhua Shi Ying Cheng Qiming Wang Kai Li Lin Wu Baohui Han Gongyan Chen Jianxing He Jie Wang Haifeng Qin Xiaoling Li | 2022 | Frontiers of Medicine2022，16，5： | 5 |
| 3 | IMPACTS OF ANTARCTIC OSCILLATION ON SUMMER MOISTURE TRANSPORT AND PRECIPITATION IN EASTERN CHINA显示文摘Using NCEP/NCAR reanalysis data and monthly precipitation over 160 conventional stations in China, analyses of moisture transport characteristics and corresponding precipitation variation in the east part of China in summer are made, and studies are carried out on possible influence on moisture transport and precipitation in summer by the variation of Antarctic Oscillation (AAO). The results show that the abnormal variation of the AAO affected the summer precipitation in China significantly. The variation of AAO can cause the variation of intension and location of Northwestern Pacific High, which in turn cause the variation of summer monsoon rainfall in the eastern China. | QINJun WANGPan-xing GONGYan | 2005 | Chinese Geographical Science2005，15，1： | 4 |
| 4 | Current management of chemotherapy-induced neutropenia in adults:key points and new challenges显示文摘Chemotherapy-induced neutropenia(CIN)is a potentially fatal and common complication in myelosuppressive chemotherapy.The timing and grade of CIN may play prognostic and predictive roles in cancer therapy.CIN is associated with older age,poor functional and nutritional status,the presence of significant comorbidities,the type of cancer,previous chemotherapy cycles,the stage of the disease,specific chemotherapy regimens,and combined therapies.There are many key points and new challenges in the management of CIN in adults including:(1)Genetic risk factors to evaluate the patient’s risk for CIN remain unclear.However,these risk factors urgently need to be identified.(2)Febrile neutropenia(FN)remains one of the most common reasons for oncological emergency.No consensus nomogram for FN risk assessment has been established.(3)Different assessment tools[e.g.,Multinational Association for Supportive Care in Cancer(MASCC),the Clinical Index of Stable Febrile Neutropenia(CISNE)score model,and other tools]have been suggested to help stratify the risk of complications in patients with FN.However,current tools have limitations.The CISNE score model is useful to support decision-making,especially for patients with stable FN.(4)There are still some challenges,including the benefits of granulocyte colony stimulating factor treatment and the optimal antibiotic regimen in emergency management of FN.In view of the current reports,our group discusses the key points,new challenges,and management of CIN. | Committee of Neoplastic Supportive-Care(CONS),China Anti-Cancer Association Committee of Clinical Chemotherapy,China Anti-Cancer Association Yi Ba Yuankai Shi Wenqi Jiang Jifeng Feng Ying Cheng Li Xiao Qingyuan Zhang Wensheng Qiu Binghe Xu Ruihua Xu Bo Shen Zhiguo Luo Xiaodong Xie Jianhua Chang Mengzhao Wang Yufu Li Yuerong Shuang Zuoxing Niu Bo Liu Jun Zhang Li Zhang Herui Yao Conghua Xie Huiqiang Huang Wangjun Liao Gongyan Chen Xiaotian Zhang Hanxiang An Yanhong Deng Ping Gong Jianping Xiong Qinghua Yao Xin An Cheng Chen Yanxia Shi Jialei Wang Xiaohua Wang Zhiqiang Wang Puyuan Xing Sheng Yang Chenfei Zhou | 2020 | Cancer Biology & Medicine2020，17，4： | 2 |
| 5 | Multi-vision Attention Networks for on-Line Red Jujube Grading显示文摘To solve the red jujube classification problem,this paper designs a convolutional neural network model with low computational cost and high classification accuracy.The architecture of the model is inspired by the multi-visual mechanism of the organism and Dense Net.To further improve our model,we add the attention mechanism of SE-Net.We also construct a dataset which contains 23,735 red jujube images captured by a jujube grading system.According to the appearance of the jujube and the characteristics of the grading system,the dataset is divided into four classes:invalid,rotten,wizened and normal.The numerical experiments show that the classification accuracy of our model reaches to 91.89%,which is comparable to Dense Net-121,Inception V3,Inception V4,and Inception-Res Net v2.Our model has real-time performance. | SUN Xiaoye MA Liyan LI Gongyan | 2019 | Chinese Journal of Electronics2019，28，6： | 2 |
| 6 | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study显示文摘 | Caicun Zhou Yi-Long Wu Gongyan Chen Jifeng Feng Xiao-Qing Liu Changli Wang Shucai Zhang Jie Wang Songwen Zhou Shengxiang Ren Shun Lu Li Zhang Chengping Hu Chunhong Hu Yi Luo Lei Chen Ming Ye Jianan Huang Xiuyi Zhi Yiping Zhang Qingyu Xiu Jun Ma Li Zhang C | 2011 | Lancet Oncology2011，，8： | 1 |
| 7 | Erlotinib versus chemo- therapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer(OPTIMAL,CTONG-0802): a multicentre,open-label,randomised,phase 3 study显示文摘 | Caicun Z Yi-Long W Gongyan C | 2011 | Lancet Oncology2011，12，8： | 1 |
| 8 | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study显示文摘 | Caicun Zhou Yi-Long Wu Gongyan Chen Jifeng Feng Xiao-Qing Liu Changli Wang Shucai Zhang Jie Wang Songwen Zhou Shengxiang Ren Shun Lu Li Zhang Chengping Hu Chunhong Hu Yi Luo Lei Chen Ming Ye Jianan Huang Xiuyi Zhi Yiping Zhang Qingyu Xiu Jun Ma Li Zhang C | 2011 | Lancet Oncology2011，，8： | 1 |
| 9 | Erlotinib versus chemotherapy as first-line treatment for patients with advanced egfr mutation-positive non-small-cell lung cancer( optimal, Ctong-0802 ) : a muhicentre, Open-label, Randomised, Phase 3 study显示文摘 | Caicun zhou Yi-long Wu Gongyan chen | 2011 | Lancet Oncology2011，12，8： | 1 |
| 10 | Different EEG ex- amination method for suspected epilepsy:epilepsy wave detection effect (with 80 eases reported)显示文摘 | Zheng Xiaogong Cui Gongyan Qi Moeold | 2009 | Journal of Harbin Institute of Medicine2009，，1： | 1 |
| 11 | Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical study显示文摘Background:Lipusu is the first commercialized liposomal formulation of pacli-taxel and has demonstrated promising efficacy against locally advanced lung squamous cell carcinoma(LSCC)in a small-scale study.Here,we conducted a multicenter,randomized,phase 3 study to compare the efficacy and safety of cis-platin plus Lipusu(LP)versus cisplatin plus gemcitabine(GP)as first-line treat-ment in locally advanced or metastatic LSCC.Methods:Patients enrolled were aged between 18 to 75 years,had locally advanced(clinical stage IIIB,ineligible for concurrent chemoradiation or surgery)or metastatic(Stage IV)LSCC,had no previous systemic chemother-apy and at least one measurable lesion as per the Response Evaluation Criteria in Solid Tumors(version 1.1)before administration of the trial drug.The primary endpoint was progression-free survival(PFS).The secondary endpoints included objective response rate(ORR),disease control rate(DCR),overall survival(OS),and safety profiles.To explore the possible predictive value of plasma cytokines for LP treatment,plasma samples were collected from the LP group at baseline and first efficacy evaluation time and were then subjected to analysis by 45-Plex ProcartaPlex Panel 1 to detect the presence of 45 cytokines using the Luminex xMAP technology.The correlation between treatment outcomes and dynamic changes in the levels of cytokines were evaluated in preliminary analyses.Results:The median duration of follow-up was 15.4 months.237 patients in the LP group and 253 patients in the GP group were included in the per protocol set(PPS).In the PPS,the median PFS was 5.2 months versus 5.5 months in the LP and GP group(hazard rtio[HR]:1.03,P=0.742)respectively.The median OS was 14.6 months versus 12.5 months in the LP and GP group(HR:0.83,P=0.215).The ORR(41.8%versus 45.9%,P=0.412)and DCR(90.3%versus 88.1%,P=0.443)were also similar between the LP and GP group.A significantly lower proportion of patients in the LP group experienced adverse events(AEs)leading to treatment interruptions(10.9%versus 26.4%,P<0.001)or treatment termination(14.3%versus 23.1%,P=0.011).The analysis of cytokine levels in the LP group showed that low baseline levels of 27 cytokines were associated with an increased ORR,and 15 cytokines were associated with improved PFS,with 14 cytokines,including TNF-a,IFN-y,IL-6,and IL-8,demonstrating an overlapping trend.Conclusion:The LP regimen demonstrated similar PFS,OS,ORR and DCR as the GP regimen for patients with locally advanced or metastatic LSCC but had more favorable toxicity profiles.The study also identified a spectrum of different cytokines that could be potentially associated with the clinical benefit in patients who received the LP regimen. | Jie Zhang Yueyin Pan Qin Shi Guojun Zhang Liyan Jiang Xiaorong Dong Kangsheng Gu Huijuan Wang Xiaochun Zhang Nong Yang Yuping Li Jianping Xiong Tienan Yi Min Peng Yong Song Yun Fan Jiuwei Cui Gongyan Chen Wei Tan Aimin Zang Qisen Guo Guangqiang Zhao Ziping Wang Jianxing He Wenxiu Yao Xiaohong Wu Kai Chen Xiaohua Hu Chunhong Hu Lu Yue Da Jiang Guangfa Wang Junfeng Liu Guohua Yu Junling Li Jianling Bai Wenmin Xie Weihong Zhao Lihong Wu Caicun Zhou | 2022 | Cancer Communications2022，42，1： | 1 |
| 12 | Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy显示文摘Background:Although programmed cell death 1(PD-1)blockade plus chemotherapy can significantly prolong the progression-free survival(PFS)and overall survival(OS)in first-line settings in patients with driver-negative advanced non-small-cell lung cancer(NSCLC),the predictive biomarkers remain undetermined.Here,we investigated the predictive value of tumor immune microenvironmental marker expression to characterize the response features to PD-1 blockade plus chemotherapy.Methods:Tumor tissue samples at baseline were prospectively collected from 144 locally advanced or metastatic NSCLC patients without driver gene alterations who received camrelizumab plus chemotherapy or chemotherapy alone.Tumor immune microenvironmental markers,including PD-1 ligand(PDL1),CD8,CD68,CD4 and forkhead box P3,were assessed using multiplex immunofluorescence(mIF)assays.Kaplan-Meier curveswere used to determine treatment outcome differences according to their expression status.Mutational profiles were compared between tumors with distinct expression levels of these markers and their combinations.Results:Responders had significantly higher CD8/PD-L1(P=0.015)or CD68/PD-L1 co-expression levels(P=0.021)than non-responders in the camrelizumab plus chemotherapy group,while no difference was observed in the chemotherapy group.Patients with high CD8/PD-L1 or CD68/PD-L1 co-expression level was associated with significantly longer PFS(P=0.002,P=0.024;respectively)and OS(P=0.006,P=0.026;respectively)than those with low co-expression in camrelizumab plus chemotherapy group.When comparing survival in the camrelizumab plus chemotherapy with chemotherapy by CD8/PD-L1 co-expression stratification,significantly better PFS(P=0.003)and OS(P=0.032)were observed in high co-expression subgroups.The predictive value of CD8/PD-L1 and CD68/PD-L1 co-expression remained statistically significant for PFS and OS when adjusting clinicopathological features.Although the prevalence of TP53 or KRAS mutations was similar between patients with and without CD8/PD-L1 or CD68/PD-L1 co-expression,the positive groups had a significantly higher proportion of TP53/KRAS co-mutations than the negative groups(both 13.0%vs.0.0%,P=0.023).Notably,enriched PI3K(P=0.012)and cell cycle pathway(P=0.021)were found in the CD8/PD-L1 co-expression group.Conclusion:Tumor immune microenvironmental marker expression,especially CD8/PD-L1 or CD68/PD-L1 co-expression,was associated with the efficacy of PD-1 blockade plus chemotherapy as first-line treatment in patients with advanced NSCLC. | Fengying Wu Tao Jiang Gongyan Chen Yunchao Huang Jianying Zhou Lizhu Lin Jifeng Feng Zhehai Wang Yongqian Shu Jianhua Shi Yi Hu Qiming Wang Ying Cheng Jianhua Chen Xiaoyan Lin Yongsheng Wang Jianan Huang Jiuwei Cui Lejie Cao Yunpeng Liu Yiping Zhang Yueyin Pan Jun Zhao LiPing Wang Jianhua Chang Qun Chen Xiubao Ren Wei Zhang Yun Fan Zhiyong He Jian Fang Kangsheng Gu Xiaorong Dong Tao Zhang Wei Shi Jianjun Zou Xuejuan Bai Shengxiang Ren Caicun Zhou | 2022 | Cancer Communications2022，42，12： | 1 |
| 13 | Erlotinib versus chemotherapy as fi rst-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer ( OPTIMAL, CTONG-0802) : a multicentre, open-label, randomised, phase 3 study显示文摘 | Caicun Zhou Yi-Long Wu Gongyan Chen | 2011 | Lancet Oncol2011，12，： | 1 |
| 14 | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer(OPTIMAL,CTONG-0802):a multicentre,open-label,rand omised,phase 3 study显示文摘 | Caichun Zhou yilong WU Gongyan Chen | | 0，，08： | 1 |
| 15 | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802 ): a multicentre, open-label, randomised, phase 3 study显示文摘 | Zhou CaiCun Wu YiLong Chen GongYan | 2011 | Lancet Oncol2011，12，8： | 1 |
| 16 | Pyridoxine regulates hair follicle development via the PI3K/Akt, Wnt and Notch signalling pathways in rex rabbits显示文摘This study was conducted to evaluate the effect of pyridoxine on the development of hair follicles in Rex rabbits and the underlying molecular mechanism.Two hundred 3-month-old Rex rabbits were randomly divided into 5 groups and fed diets supplemented with 0,5,10,20,or 40 mg/kg pyridoxine.The hair follicle density on the dorsal skin and the gene and protein expression levels of components of the phosphoinositide 3-kinase(PI3 K)/protein kinase B(PKB or Akt),Wnt,Notch and bone morphogenetic protein(BMP)signalling pathways were measured.In addition,free hair follicles were isolated from Rex rabbits and cultured with pyridoxine in vitro to measure hair shaft growth.Furthermore,dermal papilla cells(DPC)were isolated from the skin of Rex rabbits and cultured with pyridoxine in vitro to measure the gene and protein expression levels of components of the PI3 K/Akt,Wnt,Notch and BMP signalling pathways.The results showed that the addition of dietary pyridoxine significantly increased the total follicle density,secondary follicle density,and secondary-to-primary ratio(S/P,P<0.05),that the growth ratio of hair stems was promoted by pyridoxine in basic culture medium,and that the growth length of tentacle hair follicles cultured in the pyridoxine group was longer than that in the control group(P<0.05).In addition,pyridoxine changed the DPC cycle progression and promoted cell proliferation,and appropriate concentrations of pyridoxine(10 and 20μmol/L)significantly inhibited cell apoptosis(P<0.05).Pyridoxine significantly affected the gene expression of components of the PI3 K/Akt,Wnt and Notch signalling pathways in the skin and DPC of Rex rabbits(P<0.05),increased the levels of phosphorylated catenin beta 1(CTNNB1)and Akt,and decreased the level of phosphorylated glycogen synthase kinase 3 beta(GSK-3β)(P<0.05).Therefore,the molecular mechanism by which pyridoxine promotes hair follicle density in Rex rabbits probably occurs through activation of the PI3 K/Akt,Wnt and Notch signalling pathways,prolonging hair follicle growth and delaying the onset of telogen. | Gongyan Liu Guangmin Cheng Yongcui Zhang Shuxia Gao Haitao Sun Liya Bai Shu Li Yanli Zhu Chunyang Wang Fuchang Li | 2021 | Animal Nutrition2021，，4： | 1 |
| 17 | A fully absorbable biomimetic polymeric micelle loaded with cisplatin as drug carrier for cancer therapy显示文摘cis-dichlorodiammineplatinum(II)(CDDP)-loaded polymeric micelles for cancer therapy have been developed to reduce the serious side effects of cisplatin CDDP.Herein,polymeric micelles incorporated with cisplatin are prepared based on the complexation between CDDP and hydrophilic poly(L-glutamic acid)-b-poly(2-methacryloyloxyethyl phosphorylcholine)(PLG-b-PMPC)diblock copolymers.These CDDP-loaded micelles possess an average size of 91nm with narrow distribution,providing remarkable stability in media containing proteins.The release of CDDP from the micelles is faster at pH 5.0 and pH 6.0 than that at pH 7.4 and in a sustained manner without initial burst release.In addition,there is almost no difference in cellular uptake between these CDDP-loaded micelles and free CDDP.Moreover,in vitro cytotoxicity test shows they possess high efficacy to kill 4T1 cells as compared with free drug.Thus,PLG-b-PMPC copolymer might be a promising carrier for CDDP incorporating in cancer therapy. | Weihua Zhuang Boxuan Ma Gongyan Liu Xiaobing Chen Yunbing Wang | 2018 | Regenerative Biomaterials2018，5，1： | 1 |
| 18 | A biomimetic and pH-sensitive polymeric micelle as carrier for paclitaxel delivery显示文摘As nano-scale drug delivery systems,smart micelles that are sensitive to specific biological environment and allowed for target site-triggered drug release by reversible stabilization of micelle structure are attractive.In this work,a biocompatible and pH-sensitive copolymer is synthesized through bridging poly(2-methacryloyloxyethyl phosphorylcholine)(PMPC)block and poly(D,L-lactide)(PLA)block by a benzoyl imine linkage(Blink).Biomimetic micelles with excellent biocompatibility based on such PLA-Blink-PMPC copolymer are prepared as carriers for paclitaxel(PTX)delivery.Due to the rapid breakage of the benzoyl imine linkage under acidic condition,the micelle structure is disrupted with accelerated PTX release.Such pH-sensitive triggered drug release behavior in synchronization with acidic conditions at tumor site is helpful for improving the utilization of drug and facilitating antitumor efficacy.These micelles can be used as promising drug delivery systems due to their biocompatible and smart properties. | Boxuan Ma Weihua Zhuang Gongyan Liu Yunbing Wang | 2018 | Regenerative Biomaterials2018，5，1： | 1 |
| 19 | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study显示文摘 | Caicun Zhou Yi-Long Wu Gongyan Chen Jifeng Feng Xiao-Qing Liu Changli Wang Shucai Zhang Jie Wang Songwen Zhou Shengxiang Ren Shun Lu Li Zhang Chengping Hu Chunhong Hu Yi Luo Lei Chen Ming Ye Jianan Huang Xiuyi Zhi Yiping Zhang Qingyu Xiu Jun Ma Li Zhang C | 2011 | Lancet Oncology2011，，8： | 1 |
| 20 | Polyphenol based hybrid nano-aggregates modified collagen fibers of biological valve leaflets to achieve enhanced mechanical,anticoagulation and anti-calcification properties显示文摘Glutaraldehyde(Glut)-crosslinked porcine pericardium and bovine pericardium are mainly consisted of collagen and widely used for the preparation of heterogenous bioprosthetic heart valves(BHV),which play an important role in the replacement therapy of severe valvular heart disease,while their durability is limited by degeneration due to calcification,thrombus,endothelialization difficulty and prosthetic valve endocarditis.Herein,we develop a novel BHV,namely,TPly-BP,based on natural tannic acid and polylysine to improve the durability of Glut crosslinked bovine pericardium(Glut-BP).Impressively,tannic acid and polylysine could form nanoaggregates via multiple hydrogen bonds and covalent bonds,and the introduction of nanoaggregates not only improved the mechanical properties and collagen stability but also endowed TPly-BP with good biocompatibility and hemocompatibility.Compared to Glut-BP,TPly-BP showed significantly reduced cytotoxicity,improved endothelial cell adhesion,a low hemolysis ratio and obviously reduced platelet adhesion.Importantly,TPly-BP exhibited great antibacterial and in vivo anti-calcification ability,which was expected to improve the in vivo durability of BHVs.These results suggested that TPly-BP would be a potential candidate for BHV. | Shufen Li Shiying Lang Zhiqian Chen Jingruo Chen Weihua Zhuang Yangrui Du Yawen Yao Gongyan Liu Mao Chen | 2022 | Journal of Leather Science and Engineering2022，4，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员